Abstract

Objective: To compare the glycemic control of a newer insulin co-formulation, insulin degludec aspart with the conventional premixed insulin therapy, in type 2 diabetes mellitus.
Methodology: We included 120 participants with documented type 2 diabetes, taking premixed insulin therapy. They were divided into two groups; Group B participants were switched to once-daily insulin degludec aspart whereas those in group A continued receiving biphasic insulin aspart. Glycemic control was assessed with Hemoglobin A1c levels, fasting, and post-prandial plasma glucose concentrations of the participants during a 12-week study period.
Results: HbA1c, Fasting and 2-hour post prandial plasma glucose concentrations were significantly reduced in participants taking insulin degludec aspart (p

Key words: Biphasic insulin aspart, glycemic control, insulin degludec aspart, type 2 diabetes mellitus.